Consolidating the Digital Slide: How Agilent's $270M Proscia Acquisition Signals the End of Standalone Pathology AI
Dr. Dereck Mush, MD, MBA
What they do
Octopath AI is a UCL spinout developing computational pathology tools for H&E and IHC slides, with source-reported single-cell analysis in under two minutes. UCL reports £1.5 million in combined seed and grant funding led by TwinPath Ventures, including a £500,000 Innovate UK grant. The combined figure is not solely equity financing.
The record
- Vertical
- Imaging & Diagnostics
- Sub-segment
- Computational pathology
- Product type
- Platform software
- Stage
- Seed
- Headquarters
- London, UK
- Region
- Europe
- Founded
- Not disclosed
- Total funding
- Undisclosed
Also in Imaging & Diagnostics
Related on The Signal
Dr. Dereck Mush, MD, MBA
Digital Pathology Finally Has FDA-Cleared AI. Why Hospital Adoption Is Still Spotty
Dr. Dereck Mush, MD, MBA
Inside SimBioSys TumorSight Risk: Bringing Recurrence Assessment Into the MRI Workflow
Dr. Dereck Mush, MD, MBA
Beyond RECIST 1.1: The AI Endpoint Playbook for Modern Oncology Trials
Dr. Dereck Mush, MD, MBA